A5017723436- Retinoids in leukemia and cellular processes
- Estrogen and related hormone effects
- Fatty Acid Research and Health
- Genetic factors in colorectal cancer
- Antioxidant Activity and Oxidative Stress
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Inflammatory mediators and NSAID effects
- Skin Protection and Aging
- Biotin and Related Studies
- Cancer, Lipids, and Metabolism
- Helicobacter pylori-related gastroenterology studies
- Single-cell and spatial transcriptomics
- Cancer-related molecular mechanisms research
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Eicosanoids and Hypertension Pharmacology
- Colorectal Cancer Treatments and Studies
The University of Texas MD Anderson Cancer Center
2012-2023
Abstract Obesity, a cause of subclinical inflammation, is risk factor for the development postmenopausal breast cancer and associated with poorer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammatory properties. We hypothesized that treatment DHA would reduce expression proinflammatory genes aromatase, rate-limiting enzyme estrogen biosynthesis, in benign tissue overweight/obese women. A randomized, placebo-controlled, double-blind phase II study given 12...
Objective Lynch Syndrome (LS) carriers have a significantly increased risk of developing colorectal cancer (CRC) during their lifetimes. Further stratification this patient population may help in identifying additional factors that predispose to carcinogenesis. In most LS patients CRC arise from adenomas, although an alternative non-polypoid carcinogenesis pathway has been proposed for PMS2 carriers. Using data our institutional cohort, aim was describe current screening outcomes with focus...
Background Recent clinical trial data from Lynch Syndrome (LS) carriers demonstrated that naproxen administered for 6-months is a safe primary chemoprevention promotes activation of different resident immune cell types without increasing lymphoid cellularity. While intriguing, the precise enriched by remained unanswered. Here, we have utilized cutting-edge technology to elucidate activated in mucosal tissue LS patients. Methods Normal colorectal mucosa samples (pre- and post-treatment)...
Abstract Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment concentrations...
Abstract Background: Patients diagnosed with Lynch Syndrome (LS) have an approximately 70% lifetime risk of colorectal cancer (CRC) due to the presence germline mutations in mismatch repair (MMR) genes. Cyclooxygenases (COX) are key enzymes metabolism Prostaglandins (PGs) being COX-2 induced at sites inflammation as well ~85% CRC and 50% premalignant adenomas. Non-steroidal anti-inflammatory drugs (NSAIDs) such Aspirin Naproxen exert their therapeutic effects through inhibition both COX-1...
<div>Abstract<p>Obesity, a cause of subclinical inflammation, is risk factor for the development postmenopausal breast cancer and associated with poorer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammatory properties. We hypothesized that treatment DHA would reduce expression proinflammatory genes aromatase, rate-limiting enzyme estrogen biosynthesis, in benign tissue overweight/obese women. A randomized, placebo-controlled, double-blind phase...
<div>Abstract<p>Obesity, a cause of subclinical inflammation, is risk factor for the development postmenopausal breast cancer and associated with poorer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammatory properties. We hypothesized that treatment DHA would reduce expression proinflammatory genes aromatase, rate-limiting enzyme estrogen biosynthesis, in benign tissue overweight/obese women. A randomized, placebo-controlled, double-blind phase...
<div>Abstract<p>Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment...
<div>Abstract<p>Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment...